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Background. Anti-cancer treatment and the cancer population have evolved since the last European Organisation
for Research and Treatment of Cancer (EORTC) fungemia survey, and there are few recent large epidemiological studies.
Methods. This was a prospective cohort study including 145 030 admissions of patients with cancer from 13
EORTC centers. Incidence, clinical characteristics, and outcome of fungemia were analyzed.
Results. Fungemia occurred in 333 (0.23%; 95% conﬁdence interval [CI], .21–.26) patients, ranging from 0.15% in
patients with solid tumors to 1.55% in hematopoietic stem cell transplantation recipients. In 297 evaluable patients age
ranged from 17 to 88 years (median 56 years), 144 (48%) patients were female, 165 (56%) had solid tumors, and 140 (47%)
had hematological malignancies. Fungemia including polymicrobial infection was due to: Candida spp. in 267 (90%), C.
albicans in 128 (48%), and other Candida spp. in 145 (54%) patients. Favorable overall response was achieved in 113
(46.5%) patients by week 2. After 4 weeks, the survival rate was 64% (95% CI, 59%–70%) and was not signiﬁcantly dif-
ferent between Candida spp. Multivariable logistic regression identiﬁed baseline septic shock (odds ratio [OR] 3.04, 95%
CI, 1.22–7.58) and tachypnoea as poor prognostic factors (OR 2.95, 95%CI, 1.66–5.24), while antifungal prophylaxis prior
to fungemia (OR 0.20, 95% CI, .06–.62) and remission of underlying cancer (OR, 0.18; 95% CI, .06–.50) were protective.
Conclusions. Fungemia, mostly due to Candida spp., was rare in cancer patients from EORTC centers but was as-
sociated with substantial mortality. Antifungal prophylaxis and remission of cancer predicted better survival.
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Candidemia occurs frequently, is a severe clinical com-
plication, and is associated with high morbidity and
mortality, particularly in patients being treated for can-
cer [1–3].Yet the epidemiology of fungemia in these pa-
tients has not been fully elucidated [4].
In the 1990s the European Organisation for Research
and Treatment of Cancer (EORTC) conducted a study
of fungemia in patients undergoing treatment of solid
tumors or hematological cancers [5]. Of 270 episodes,
92% were caused by Candida spp., and key results
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showed an association of Candida glabrata infection, advanced
age, and disease severity with mortality. Since then epidemiol-
ogy may have changed for several reasons: A changing distribu-
tion of Candida species has been reported [6], additional
antifungal drugs have become available, particularly the echino-
candin class [7, 8], indications for immunosuppressive therapy,
and for hematopoietic stem cell transplantation (HSCT) in par-
ticular have increased [9], and early antifungal treatment in-
cluding prophylaxis has been adopted [10–12].
We have conducted a second study of the epidemiology of fun-
gemia in cancer. Objectives of this study were to determine fungal
pathogen distribution, prognostic factors for outcome, and crude
and attributable mortality. An additional aim of this study was to
describe the incidence of fungemia in relation to the number of
hospital admissions of adult cancer patients in Europe.
MATERIAL AND METHODS
This intergroup study was sponsored by the EORTC (protocol
65031) and conducted in collaboration with the Infectious Dis-
ease Working Party of the German Society for Hematology and
Oncology and the Infectious Disease Working Party of the Eu-
ropean Group for Blood and Marrow Transplantation. Centers
afﬁliated with these Infectious Diseases Groups were invited to
participate.
The protocol was approved by the ethics committees and in-
stitutional review boards of the participating centers. Two
groups of patients were selected. Group A comprised all admis-
sions to the participating wards of patients ≥18 years of age with
a diagnosis of a solid tumor, hematological malignancy, and/or
recipients of any type of HSCT. Admission was deﬁned as ≥1
night’s in-hospital stay. Group B, a subgroup of group A, in-
cluded all patients who had a fungus isolated from ≥1 blood
culture and for whom there was signed informed consent.
Once the eligibility criteria were fulﬁlled, patients from group
B were prospectively registered at the EORTC Data Center by
telephone or web access. Patients could only be registered
once. Case report forms were completed either in paper form
or by electronic remote data capture. For this epidemiologic
study approximately 300 fungemia patients were expected
over a study period of 2 years. As this was a noninterventional
study, no randomization or stratiﬁcation was done. and no ad-
verse events were to be reported.
Fungal isolates were sent to the EORTC-IDG Mycology Ref-
erence Laboratory for Yeasts, Institute of Microbiology, Lau-
sanne University Hospital, Lausanne, Switzerland for purity
check, and conﬁrmation of identiﬁcation, which overruled
identiﬁcation done by the study sites. Only Candida isolates
were tested for their susceptibility to ﬂuconazole, voriconazole,
posaconazole, amphotericin B by EUCAST, and caspofungin by
the CLSI method.
Criteria evaluated for group A were reporting period (date of
ﬁrst patient in to date of last patient out), number of admissions
of patients with a diagnosis of malignant disease or HSCT, type
of transplantation, number of admissions of patients by type of
solid tumor or hematological malignancy during the reporting
period and number of admissions of patients with a document-
ed fungemia by underlying disease type. These summary data
were collected at regular time intervals during the reporting pe-
riod. Additional information collected for group B patients were
demographics, details of malignant disease and predisposing
factors for the development of fungemia, such as previous sur-
gery, radiotherapy, antibiotics, total parenteral nutrition, major
organ dysfunction, presence of neutropenia, antifungal prophy-
laxis and treatment, date of diagnosis of fungemia, number and
source of positive blood cultures, clinical signs and symptoms of
fungemia, and organ involvement.
Group B patients were followed up to 12 weeks from diagno-
sis of fungemia, and data were collected on antifungal treat-
ment, clinical and microbiological response, and survival.
Treatment was considered adequate when the isolate was sus-
ceptible to the initial treatment. Response to treatment was de-
termined at weeks 2, 4, and 12. Clinical evaluation of response
was categorized as follows: Complete response (complete reso-
lution of clinical signs and symptoms of fungemia), partial re-
sponse (signiﬁcant but incomplete resolution of clinical signs
and symptoms), stable disease (no signiﬁcant improvement in
clinical signs and symptoms), and progressive disease (wor-
sening of clinical signs and symptoms). Microbiological evalu-
ation of response was categorized as complete microbiological
response (3 consecutive negative blood cultures), no microbio-
logical response (persistently positive blood cultures), and
microbiological relapse (complete microbiological response fol-
lowed by a positive blood culture within the 12 week follow-up).
If no follow-up blood cultures were obtained, microbiological
response was categorized as not assessable. Global response
was deﬁned as complete or partial clinical response with com-
plete microbiological response.
Survival data were graphically presented by Kaplan–Meier
curves and compared by using log rank test. We considered 2
binary outcomes: death within 4 weeks, and favorable overall re-
sponse at 2 weeks. Differences in categorical variables were as-
sessed with χ2 and Fisher exact tests, differences in continuous
variables were assessed with t-test and Mann–Whitney test.
Multivariable logistic regression models were built with step-
wise variable selection. All statistical analyses were done with
SAS 9.3 (SAS Institute Inc., Cary, North Carolina).
Explanatory variables considered for the outcomes of “favor-
able overall response at 2 weeks” and “death within 4 weeks”
were: age, gender, underlying disease and its status, time inter-
val between hospital admission to onset of fungemia, HSCT,
treatment given within 30 days before diagnosis (chemotherapy,
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radiation therapy, immunosuppressive drugs, major surgical
procedure, total parenteral nutrition, antibacterials, antifungals),
neutropenia, colonization at baseline, signs and symptoms,
organ involvement, catheter correlation (whether after removal
of the central venous catheter the same pathogen was found as
previously isolated in blood culture), and the pathogen.
RESULTS
From 1 January 2005 to 2 November 2009, a total of 145 030
cancer patients were admitted to 13 participating centers in 8
countries. Fungemia was diagnosed in 333 of these patients.
The overall incidence rate was 0.23%, ranging from 0.15% in
solid tumor patients to 1.55% in HSCT recipients. Incidence
rates according to underlying malignancy are listed in Table 1.
We excluded 36 patients for whom no detailed data were ob-
tained, mostly because they did not provide informed consent.
Of the remaining 297 patients with fungemia (Group B), 165
(56%) had a solid tumor, 140 (47%) patients had a hematolog-
ical malignancy, and 50 (17%) underwent HSCT. Baseline char-
acteristics including potential risk factors for fungemia are
detailed in Table 2.
General signs and symptoms at diagnosis of fungemia were
fever >37°C (98.6°F) in 93% (275/297), ≥38°C (100.4°F) in
76% (225/297), septic shock in 10% (30/297), tachycardia in
70% (204/292), tachypnoea in 33% (95/290), myalgia in 20%
(53/271), and chills in 30% (88/293) of the patients.
At baseline, organ involvement was evaluated in 265 (89%)
patients, whereas data were missing for 32 (11%) patients.
Organs were involved in 83 of 265 (31%) patients. These
were skin in 13 (5%), liver/spleen in 12 (5%), kidney/urinary
tract in 10 (4%), other intraabdominal involvement in 9
(3%), endocardium in 6 (2%), eye in 6 (2%), vascular in 3
(1%), and central nervous system (CNS) in 2 (<1%) patients.
Organ involvement decreased from 31% (83/265) at baseline
to 16% (9/55) in week 12.
Of 251 (85%) patients with central vascular device the cath-
eter was retained in 84 (33%), whereas it was removed in 167
(67%) patients, a median of 3 days after diagnosis of fungemia
(range, 0–112 days). Removed catheters were cultured in 91%
(152/167) of patients. Of 152 catheter cultures, 69 (45%) showed
fungal growth. In 67 (97%) of them the same fungal species as
in the initial blood culture was found.
Fungemia was caused by a single pathogen in 288 (97%) pa-
tients, 9 (3%) patients had infections due to more than 1 species,
resulting in a total of 306 isolates. Pathogens are listed according
to underlying diseases and HSCT in Table 3. Candida species
accounted for 274 (90%) isolates. Central review of fungal path-
ogens was offered to all centers except the reference center itself
(35 isolates), for which correct identiﬁcation was taken for
granted. Of the remaining 271 pathogens, central reviews for
172 (63%) were available. Isolate identiﬁcation by the sites
was conﬁrmed by the reference laboratory in 164 (95%) cases.
Misidentiﬁed isolates were found in 8 cases, and these were
evenly distributed across study sites; details are given in Table 3.
Full susceptibility tests were done for 141 isolates of Candida
spp. All 63 C. albicans and 17 C. parapsilosis isolates were sus-
ceptible to all antifungals. Of 27 C. tropicalis all but 2 strains
were susceptible to all the antifungals, whereas the 2 remaining
strains were only susceptible to posaconazole and amphotericin
B. EUCAST deems that there is insufﬁcient evidence to consider
C. glabrata and C. krusei as good targets for treatment with
Table 1. Fungemia Incidence Rates by Underlying Malignancy
(Fungemia Patients per Admissions)
Patient Group
Incidence
[% (95% CI)]
Patients With
Fungemia per
Observed Group; N/N
Overall 0.23% (.21–.26) 333/145 030
Solid tumor without
HSCT
0.15% (.13–.18) 174/114 811
Gastro-intestinal 0.37% (.30–.46) 88/23 718
Lung 0.05% (.01–.11) 5/10 976
Breast 0.05% (.02–.10) 8/16 137
Genito-urinary 0.20% (.14–.27) 42/21 389
Head and Neck 0.13% (.08–.20) 24/18 248
Other 0.03% (.01–.06) 7/24 343
Solid tumor with HSCT 1.55% (.19–5.49) 2/129
Allogeneic HSCT 1/5
Autologous HSCT 0.81% (.02–4.41) 1/124
Hematological
malignancies
without HSCT
0.42% (.35–.50) 114/27 195
ALL 0.64% (.38–1.01) 18/2801
AML 0.89% (.63–1.21) 39/4403
CLL 0.29% (.09–.67) 5/1738
CML 0.37% (.04–1.32) 2/543
MDS 0.57% (.19–1.33) 5/875
Lymphoma 0.29% (.21–.40) 38/12 933
Multiple myeloma 0.15% (.05–.35) 5/3356
Other 0.37% (.04–1.32) 2/546
Hematological
malignancies with
HSCT
1.46% (1.06–1.97) 42/2871
Allogeneic HSCT –
related donor
2.10% (1.18–3.44) 15/715
Allogeneic HSCT –
unrelated donor
1.99% (1.00–3.54) 11/552
Autologous HSCT 1.00% (.57–1.61) 16/1604
HSCT without
associated
malignancies
1/24
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid
leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML,
chronic myeloid leukemia; HSCT, hematopoietic stem cell transplantation;
MDS, myelodysplastic syndrome.
326 • CID 2015:61 (1 August) • Cornely et al
azole antifungals. The 19 C. glabrata and all 15 C. krusei were
susceptible to amphotericin B, but 3 C. glabrata and 5 C. krusei
were resistant to caspofungin.
The median time from blood culture sampling to initiation of
antifungal treatment was 2 days, with a minimum of 0 and a
maximum of 21 days. A total of 242 (81%) patients received
treatment for fungemia, and 228 started with antifungal treat-
ment within the ﬁrst week. Of these 6 (3%) received antifungal
combination therapy, 53 (23%) received >1 antifungal sequen-
tially in the ﬁrst week, and 169 (74%) received a single antifungal:
32 (14%) intravenous amphotericin B, 51 (22%) echinocandin, 79
(35%) ﬂuconazole, 6 (3%) voriconazole, and 1 (0.4%) other. Only
14 of 228 (6%) patients receiving initial intravenous treatment
were switched to an oral antifungal within the ﬁrst week after di-
agnosis. The pathogens cultured fell within the spectrum of the
antifungals chosen for treatment in 226 of 297 (76%) cases.
Overtly incorrect treatment decisions, such as initiating an anti-
fungal despite known resistance, were infrequent. Overall, 55
(19%) patients did not receive antifungal treatment, and 14 pa-
tients received treatment more than 7 days post diagnosis of fun-
gemia. No antifungal treatment at all was given to 27 of 118
(23%) patients with C. albicans fungemia and to 20 of 140
(14%) patients with candidemia due to other species (P = .08).
Breakthrough fungemia, deﬁned as patients being treated for
≥1 day before the ﬁrst positive blood culture was drawn, oc-
curred in 69 (23%) patients. Most of these infections were
caused by a single species; 2 were due to more than 1 species.
Breakthrough candidemia was due to: C. albicans (14; 20%)
and Candida other than C. albicans (38; 55%), namely C. krusei
(15; 22%), C. glabrata (5; 7%), C. tropicalis (6; 9%), C. parapsi-
losis (5; 7%), C. norvegensis (2; 3%), C. dubliniensis (1; 1%),
C. kefyr (2; 3%), and Candida spp. (2; 3%). Two infections
were caused by more than 1 species: C. albicans & C. glabrata
and C. albicans and C. parapsilosis. In 10 (14%) patients break-
through pathogens were noncandida yeast: Trichosporon spp.
(5; 7%), Saprochaete capitata (formerly Geotrichum capitatum)
(2; 3%), S. clavata (1; 1%), Cryptococcus laurentii (1; 1%), and
Saccharomyces sp. (1; 1%). Other positive blood cultures classi-
ﬁed as breakthrough infections grew molds in 1 patient each:
Fusarium sp., Syncephalastrum racemosum, Rhizopus oryzae,
Table 2. Baseline Characteristics of European Patients With
Cancer and Fungemia (N = 297)
Characteristic Value N/N
Age, median (min – max) 56 (17–88)
Sex, male 153/297 (52%)
Days from hospital admission to
diagnosis of fungemia, mean ± std
23 ± 21
Neutropenia <500 cells/µL at time
of diagnosis of fungemia
110/286 (38%)
Vascular access device upon
fungemia diagnosis
280/297 (94%)
Central venous catheter 238/297 (80%)
Peripheral catheter 29/297 (10%)
Both 13/297 (4%)
Underlying disease
Solid Tumora 165/297 (56%)
Gastro-intestinal 74/165 (45%)
Lung 6/165 (4%)
Breast 9/165 (5%)
Genito-urinary 41/165 (25%)
Head and neck 23/165 (14%)
Other 11/165 (7%)
Unknown 1/165 (0.6%)
Hematologicala 140/297 (47%)
Acute lymphoblastic leukemia 23/140 (16%)
Acute myelogenous leukemia or
myelodysplastic syndrome
60/140 (43%)
Lymphoma incl. chronic
lymphocytic leukemia
44/140 (31%)
Other 13/140 (9%)
HSCT without associated
malignancy
1/297 (0.3%)
Status of malignancy
Solid Tumora
At diagnosis 29/165 (18%)
Complete or partial remission 29/165 (18%)
No change or progressive disease 107/165 (65%)
Hematological malignancya
Onset 19/140 (14%)
Complete remission 20/140 (14%)
Partial remission, bone marrow
hypoplasia, refractory, or relapse
101/140 (72%)
Treatment at fungemia diagnosis
HSCT 50/297 (17%)
Allogeneic HSCT 28/297 (9%)
Autologous HSCT 22/297 (7%)
Chemotherapyb 142/296 (48%)
Radiation therapyb 22/296 (7%)
Immunosuppressive drugsb 88/293 (30%)
Major surgical procedureb 69/297 (23%)
Total parenteral nutritionb 118/295 (40%)
Stopped prior to fungemia
diagnosis
36/295 (12%)
On-going at fungemia diagnosis 82/295 (28%)
Antibioticsb 255/297 (86%)
Table 2 continued.
Characteristic Value N/N
Antifungalsb 89/297 (30%)
Prophylactic 32/297 (11%)
Empiric or curative 57/297 (19%)
Abbreviation: HSCT, hematopoietic stem cell transplantation.
a 9 patients had both a solid tumor and a hematological malignancy.
b Within 30 days prior to diagnosis of current fungemia episode.
Fungemia in Cancer Patients • CID 2015:61 (1 August) • 327
and Paecilomyces species. Breakthrough fungemia was treated in
57 (83%) patients, while 12 (17%) received no antifungal drugs.
The median time to new antifungal treatment was 2 days (range
0 to 21 days).
Global response was achieved in 87 (36%) and 26 (11%)
evaluable patients by week 2. Seven (6%) patients had a micro-
biological relapse, which occurred between day 29 and day 62.
At week 2, treatment response was not assessed in 46 (15%) pa-
tients, and 8 (3%) patients were lost to follow-up. Of the re-
maining 243 patients, 69 (28%) had died and thus were
regarded as treatment failures, and 61 (25%) patients had either
failed treatment or fungemia had relapsed. In total, treatment
failure was observed in 130 of 243 (53.5%) evaluable patients. In
a multivariable logistic regression model baseline characteristics
predicting a higher risk of failure were tachycardia (odds ratio
[OR] 2.07, 95% conﬁdence interval [CI], 1.10–3.92, P = .03),
myalgia (OR 2.37, 95% CI, 1.13–4.98, P = .02), and septic
shock (OR 3.57, 95% CI, 1.30–9.80, P = .01).
Overall mortality was 35% and 49% at weeks 4 and 12 (Fig-
ure 1). For patients who had achieved clinical complete re-
sponse, partial response, or stable disease 2 weeks after
diagnosis of fungemia the crude week 4 survival rate was 86%.
In contrast, 4 week survival in patients with progressive fungal
disease was 58% (P < .001).
Investigators attributed 50 (72%) of the deaths within the ﬁrst
2 weeks to fungemia. Survival rates did not differ between
Table 3. Fungia Isolated From Blood Cultures in European Patients With Cancer, by Underlying Disease and Treatment Groups (N = 297)
Pathogen Isolated by
Treating Center
Total n = 297
(%)
Solid Tumorb
n = 165 (%)
Hematological
Malignancyb
n = 140 (%)
Allogeneic HSCT
n = 28 (%)
Autologous HSCT
n = 22 (%)
No Transplant
n = 247 (%)
Single pathogen 288 (97.0%) 159 (97%) 137 (98%) 27 (96.4%) 22 (100%) 239 (96.8%)
Candida albicans 120 (40.4%) 92 (56%) 31 (22%) 2 (7.1%) 7 (31.8%) 111 (44.9%)
Non-albicans candida 138 (46.5%) 59 (36%) 82 (59%) 21 (75.0%) 12 (54.6%) 105 (42.5%)
C. glabrata 29 (9.8%) 25 (15.2%) 6 (4.3%) 1 (3.6%) 1 (4.5%) 27 (10.9%)
C. tropicalis 39 (13.1%) 11 (6.7%) 30 (21.4%) 2 (7.1%) 4 (18.2%) 33 (13.3%)
C. parapsilosis 28 (9.4%) 16 (9.7%) 11 (7.9%) 5 (17.9%) 2 (9.1%) 21 (8.5%)
C. krusei 25 (8.4%) 5 (3.0%) 20 (14.3%) 6 (21.4%) 4 (18.2%) 15 (6.1%)
C. kefyr 7 (2.4%) 1 (<1%) 6 (4.3%) 2 (7.1%) 1 (4.5%) 4 (1.6%)
C. norvegensis 3 (1.0%) . . . 3 (2.1%) 1 (3.6%) . . . 2 (0.8%)
C. dubliniensis 2 (<1%) . . . 2 (1.4%) 1 (3.6%) . . . 1 (0.4%)
C. guilliermondii 2 (<1%) 1 (<1%) 1 (<1%) 1 (3.6%) . . . 1 (0.4%)
C. rugosa 1 (<1%) . . . 1 (<1%) . . . . . . 1 (0.4%)
Other Candidac 2 (<1%) . . . 2 (1.4%) 2 (7.1%) . . . . . .
Non-candida yeastd 17 (5.7%) 5 (3%) 13 (9%) 2 (7.1%) 2 (9.1%) 13 (5.3%)
Cryptococcus sp. 4 (1.3%) 1 (<1%) 3 (2%) . . . . . . 4 (1.6%)
Mold, NOSe 7 (2.4%) 1 (<1%) 7 (5%) 2 (7.1%) 1 (4.6%) 4 (1.6%)
Trichoderma
longibrachiatum
2 (<1%) 1 (<1%) 1 (<1%) . . . . . . 2 (<1%)
Two pathogens isolated 9 (3%) 6 (3%) 3 (2%) 1 (3.6%) . . . 8 (3.2%)
Candida albicans and non-
albicans candidaf
6 (2.0%) 4 (2.4%) 2 (1.4%) . . . . . . 6 (2.4%)
Candida albicans and non-
candida yeastg
2 (<1%) 2 (1.2%) . . . . . . . . . 2 (<1%)
Non-albicans candidah 1 (<1%) . . . 1 (<1%) 1 (3.6%) . . . . . .
Abbreviations: HSCT, hematopoietic stem cell transplantation; NOS, not otherwise specified.
a Identified by local laboratory.
b 9 had both, a solid tumor and a hematological malignancy.
c 2 NOS.
d 8 Trichosporon spp., 4 Saprochaete capitata, 1 S. clavata, 2 Saccharomyces spp., 1 S. cerevisiae, 1 NOS.
e 3 Fusarium spp., 1 Rhizopus oryzae, 1 Syncephalastrum racemosum, 1 Paecilomyces sp., 1 NOS.
f 4 C. glabrata, 2 C. parapsilosis.
g 2 NOS.
h 1 C. norvegensis, 1 C. inconspicua. The following isolates were reclassified by the central laboratory: C. albicans → C. dubliniensis, C. glabrata → C. krusei,
C. rugosa → G. capitatum, C. dubliniensis → C. albicans, C. albicans → C. parapsilosis, C. albicans → C. tropicalis, C. krusei → C. parapsilosis, Trichosporon
asahii → C. tropicalis. For mold infections other than fusariosis this study could not rule out contamination rather than blood stream infection.
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patient groups with fungemia due to C. albicans, non-albicans
Candida and noncandida yeasts. When comparing survival
rates for fungemia caused by the most frequent Candida spp.,
no difference was found between C. albicans, C. glabrata,
C. tropicalis, C. parapsilosis, and C. krusei (Figure 2).
For 33 (11%) patients follow-up was less than 1 month, so
that 264 (89%) patients underwent analysis of baseline factors
potentially prognostic for 28-day survival. Multivariable logistic
regression identiﬁed presence of septic shock (OR 3.04, 95% CI,
1.22–7.58) and tachypnoea as negative prognostic factors (OR
2.95, 95% CI, 1.66–5.24). Positive prognostic factors were remis-
sion of underlying malignancy (OR 0.18, 95% CI, .06–.50) and
antifungal prophylaxis at any time within 30 days prior to diag-
nosis of fungemia (OR 0.20, 95% CI, .06–.62). Median time to
central venous catheter removal was 3 days and removal vs no
removal had no impact on 28-day survival. Comparing patients
with deep seated organ involvement (CNS, eye, heart/endocar-
ditis, kidney/urinary tract infection, liver/spleen, skin) and
patients without documented organ involvement, risk of
death at day 28 did not differ.
DISCUSSION
In a large multinational study in cancer patients the overall in-
cidence of fungemia was 0.23% and ranged from 0.15% in solid
tumor patients to 1.55% in HSCT recipients [13]. In gastrointes-
tinal cancer, fungemia rates were comparably higher than with
other tumors, which reﬂects abdominal surgery as a risk factor
for invasive candidiasis [14].
An epidemiological shift from C. albicans to other Candida
spp. is an ongoing discussion, but published data are inconsis-
tent, probably reﬂecting local epidemiology, rather than global
trends [15, 16]. The proportion of C. albicans among candide-
mias (47%) was similar to the previous EORTC study (49%) [5].
In both studies non-albicans Candida species were more fre-
quent in hematological disease than with solid tumors [5].
One potential explanation is higher selection pressure due to
more extensive antifungal exposure in hematology [17]. Molds
other than Fusarium spp. isolated from blood cultures techni-
cally fulﬁl the deﬁnition of fungemia, but contamination cannot
be excluded, if isolated only from a single blood culture [18]. A
limitation of our noninterventional study is the absence of a
standardized evaluation of organ involvement, which may
have been underestimated.
Contrary to the overall species distribution, pathogens found
in breakthrough fungemia were C. albicans in 20% only. A re-
cent overview of >100 clinical trials evaluating antifungal pro-
phylaxis found similar results, likely because C. albicans is
effectively treated by the systemically active antifungals used
in these trials as well as in our study [19, 20]. Another ﬁnding
of our study is the continuing low resistance rate of C. albicans
in this population, despite high azole usage. This has been de-
scribed previously in a longitudinal evaluation during long-
term azole exposure [19].
Central catheters were removed after a median of 3 days,
reﬂecting a median of 2 days from obtaining blood cultures
to observing fungal growth. Current guidelines recommend
removing any indwelling lines once fungemia is diagnosed be-
cause of likely bioﬁlm formation [21–23]. But central venous
devices present at onset of fungemia were retained in a third
of patients, and 19% of all fungemia patients did not receive
any antifungal treatment. These remarkable ﬁndings may be ex-
plained by our broad enrolment criteria including patients with
minimized treatment interventions in palliative settings. Treat-
ment response in our study was lower than in recent large ran-
domized clinical trials, again emphasizing healthier patient
populations in phase 3 trials [24–26].Mortality rates were com-
parably higher in our study, but mortality did not correlate
with fungal species, although in the previous EORTC study
Figure 1. Overall survival in 297 European cancer patients with
fungemia.
Figure 2. Species-speciﬁc survival in 275 European cancer patients with
candidemia (P value .14, overall test).
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C. glabrata was associated with worse outcome [5]. Both anti-
fungal prophylaxis and remission of malignant disease indepen-
dently protected from adverse outcome. Between the 2 study
periods, antifungal management underwent major develop-
ments, such as the introduction and more widespread use of
broad spectrum antifungals, which are now frequently used. It
is also encouraging that fungal species were correctly identiﬁed
on-site in the vast majority of cases.
This epidemiological study covers the years 2005–2009.
Whether all ﬁndings are applicable to 2015 is not clear, and ep-
idemiological developments need continuous observation.
In summary, we have deﬁned the fungemia rate in patients
with cancer for the ﬁrst time and described recent changes in
prognostic factors [17, 21, 23].
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